"id","uuid:ID","rationale","versionIdentifier","instanceType"
"StudyVersion_1","65638816-2c6b-441c-979a-2d8009c207e4","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","2","StudyVersion"
